SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-041271
Filing Date
2023-12-12
Accepted
2023-12-12 07:15:21
Documents
14
Period of Report
2023-12-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cccc-20231212.htm   iXBRL 8-K 35141
2 EX-99.1 cccc-20231212xexx991.htm EX-99.1 13101
6 c4tlogo1.jpg GRAPHIC 8913
  Complete submission text file 0001628280-23-041271.txt   196167

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cccc-20231212.xsd EX-101.SCH 1948
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cccc-20231212_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cccc-20231212_pre.xml EX-101.PRE 13088
8 EXTRACTED XBRL INSTANCE DOCUMENT cccc-20231212_htm.xml XML 2818
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

IRS No.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39567 | Film No.: 231479945
SIC: 2836 Biological Products, (No Diagnostic Substances)